CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor anti...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
We are very excited to launch our new website! Please take a few moments to click around and explore...
CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The ...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
CTS Dallas and Phoenix Labs successfully implemented WNV NAT testing on the Panther Testing Platform...